Novo Nordisk | NVO - Sales Revenues


Novo Nordisk reported DKK12.53B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bausch Health Companies USD 2.5B 300M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Novo Nordisk DKK 12.53B 2.44B Dec/2025
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Zoetis USD 2.3B 100M Mar/2026